On September 12, 2023, 2seventy bio held a conference call (webcast / press release) announcing the strategic restructuring of the company’s business operations and R&D model. Measures include a 40% workforce reduction and a pipeline reprioritization and are driven by a projected decrease in Abecma’s (BMS / 2seventy BCMA CAR-T) revenue for 2023. Additionally, the company disclosed Nick Leschly’s decision to step down as CEO. On the same day, 2seventy announced the expansion of its collaboration with JW Tx adding 2 new assets from its pipeline: a solid tumor targeting TCR-T and a CAR-T for autoimmune diseases (press release). Below, Celltelligence provides insights on 2seventy’s new Abecma revenue projections for 2023 and the collaborative R&D model that the company aims to implement for its pipeline.